FrancophonIA/ELRC3.0 huggingface dataset:
English: When administration of HMG CoA reductase inhibitors and REZOLSTA is desired, it is recommended to start with the lowest dose and titrate up to the desired clinical effect while monitoring for safety.
Croatian: Kada je poželjna primjena inhibitora HMG CoA reduktaze i lijeka REZOLSTA, preporučeno je započeti s najnižom dozom i titrirati ju na višu do željenog kliničkog učinka i pri tom pratiti sigurnost.
English: There is no specific antidote for overdose with REZOLSTA.
Croatian: Ne postoji specifičan antidot za predoziranje lijekom REZOLSTA.
English: Dizziness has been reported in some patients during treatment with regimens containing darunavir administered with cobicistat and should be borne in mind when considering a patient's ability to drive or operate machinery.
Croatian: Prijavljena je omaglica kod nekih bolesnika tijekom liječenja režimima koji su sadržavali darunavir primijenjen istodobno s kobicistatom, što se mora imati na umu kada se procjenjuje bolesnikova sposobnost vožnje ili upravljanja strojevima.
English: Dose adjustment for buprenorphine may not be necessary when co-administered with REZOLSTA but a careful clinical monitoring for signs of opiate toxicity is recommended.
Croatian: Prilagodba doze buprenorfina možda neće biti potrebna kada se primjenjuje istodobno s lijekom REZOLSTA ali se preporučuje pažljivo kliničko praćenje znakova opijatne toksičnosti.
English: This may be more likely with long-term HIV treatment, more severe damage to the immune system, overweight, or the use of alcohol or other medicines called corticosteroids.
Croatian: Njena pojava može biti vjerojatnija tijekom dugotrajnog liječenjaHIV-a, uz teže oštećenje imunološkog sustava, prekomjernu težinu ili uzimanje alkohola ili drugih lijekova koji ze zovu kortikosteroidi.
English: During the darunavir/ritonavir clinical development program (N = 3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients.
Croatian: Tijekom kliničkog razvojnog programa darunavira/ritonavira (N = 3063), teške kožne reakcije, koje mogu biti praćene vrućicom i/ili povišenim transaminazama, bile su prijavljene u 0,4% bolesnika.
English: If these anti-depressants are to be used with REZOLSTA clinical monitoring is recommended and a dose adjustment of the anti-depressant may be needed.
Croatian: Ako se ti antidepresivi trebaju uzimati s lijekom REZOLSTA preporučuje se kliničko praćenje i može biti potrebna prilagodba doze antidepresiva.
English: Clinical monitoring is recommended when co-administering REZOLSTA with beta-blockers and a lower dose of the beta-blocker should be considered.
Croatian: Preporučuje se kliničko praćenje kada se lijek REZOLSTA istodobno primjenjuje s beta-blokatorima, te se mora uzeti u obzir niža doza beta-blokatora.
English: With HIV-1 clade Type B
Croatian: S podtipom HIV-1 Tip B Tip AE Tip C Ostalo
English: Very common side effects (may affect more than 1 in 10 people) - headache - diarrhoea, nausea.
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - glavobolja - proljev, mučnina.
English: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART).
Croatian: Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s općepoznatim faktorima rizika, uznapredovalom HIV bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji (KART).
English: * DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V.
Croatian: 6/l (vidjeti dio 4.1). * DRV-RAM: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V.
English: Liver problems that may occasionally be severe have been reported.
Croatian: Prijavljene su tegobe s jetrom, koje ponekad mogu biti teške.
English: The risk of muscle damage might be increased.
Croatian: Moguć je povećan rizik od oštećenja mišićnog tkiva.
English: The plastic bottle comes with a child resistant cap and must be opened as follows: Push the plastic screw cap down while turning it counter clockwise.
Croatian: Plastična boca ima zatvarač siguran za djecu i treba ju otvarati na sljedeći način: Pritisnite plastični zatvarač s navojem prema dolje dok ga okrećete u smjeru suprotnom od kazaljke na satu.
English: The table below shows the development of HIV-1 protease mutations and loss of susceptibility to HIV PIs in virologic failures at endpoint in the GS-US-216-130, ARTEMIS and ODIN trials.
Croatian: Tablica ispod pokazuje razvoj mutacija HIV-1 proteaza i gubitak osjetljivosti na HIV PI kod viroloških neuspjeha na ishodu ispitivanja GS-US-216-130, ARTEMIS i ODIN.
English: Careful patient monitoring and dose adjustment of metformin is recommended in patients who are taking REZOLSTA.
Croatian: Preporučuje se pažljivo praćenje bolesnika i prilagodba doze metformina u bolesnika koji uzimaju lijek REZOLSTA.
English: Your doctor will advise you how to deal with your symptoms or whether REZOLSTA must be stopped.
Croatian: Liječnik će Vam savjetovati što učiniti vezano uz pojavu simptoma i morate li prestati s uzimanjem lijeka REZOLSTA.
English: ANAESTHETIC Alfentanil
Croatian: ANESTETICI Alfentanil
English: Pack size of one bottle.
Croatian: Veličina pakiranja: jedna boca po kutiji.
English: Iron oxide red
Croatian: Željezov oksid, crveni
English: If this is noticed later than 12 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.
Croatian: Ako je primijećeno da je doza propuštena više od 12 sati nakon uobičajenog vremena uzimanja lijeka, propuštena doza se ne smije uzeti, a bolesnik mora ponovno nastaviti s uobičajenim rasporedom doziranja.
English: REZOLSTA and artemether/lumefantrine can be used without dose adjustments; however, due to the increase in lumefantrine exposure, the combination should be used with caution.
Croatian: Kombinacija lijeka REZOLSTA i artemetera/lumefantrina može se primijeniti bez prilagodbe doze, međutim, zbog povećane izloženosti lumefantrinu, tu kombinaciju se mora primjenjivati s oprezom.
English: The activity of cobicistat as a pharmacokinetic enhancer to darunavir has been demonstrated in pharmacokinetic trials.
Croatian: Aktivnost kobicistata kao farmakokinetičkog pojačivača za darunavir dokazana je u farmakokinetičkim ispitivanjima.
English: Clinical monitoring is recommended when co-administering REZOLSTA with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered.
Croatian: Preporučuje se kliničko praćenje kada se REZOLSTA primjenjuje istodobno s tim sedativima/hipnoticima i u obzir se mora uzeti niža doza sedativa/hipnotika.
English: If REZOLSTA is co-administered with parenteral midazolam, it should be done in an intensive care unit or similar setting, which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Croatian: Ako se REZOLSTA istodobno primjenjuje s parenteralno primijenjenim midazolamom, primjena bi morala biti u jedinici intenzivnog liječenja ili sličnom odjelu gdje je osigurano pomno kliničko praćenje, te primjereno medicinsko zbrinjavanje u slučaju respiratorne depresije i/ili produljene sedacije.
English: Human experience of acute overdose with REZOLSTA or darunavir in combination with cobicistat is limited.
Croatian: Iskustvo akutnog predoziranja kod ljudi lijekom REZOLSTA ili darunavirom u kombinaciji s kobicistatom je ograničeno.
English: Both arms used a fixed background regimen consisting of tenofovir disoproxil fumarate 300 mg once daily and emtricitabine 200 mg once daily.
Croatian: U obje skupine primijenjen je optimizirani osnovni režim koji se sastojao od tenofovirdizoproksilfumarata 300 mg jedanput na dan i emtricitabina 200 mg jedanput na dan.
English: It is recommended that HIV infected women must not breast-feed their infants because of both the possibility of your baby becoming infected with HIV through your breast milk and because of the unknown effects of the medicine on your baby.
Croatian: Preporučeno je da žene zaražene HIV-om ne smiju dojiti dijete zbog mogućnosti prijenosa HIV-a na dijete putem majčina mlijeka te zbog nepoznatih učinaka koje lijek može imati na Vaše dijete.
English: HIV-RNA
Croatian: HIV-RNK
English: Darunavir The absolute oral bioavailability of a single 600 mg dose of darunavir alone is approximately 37%.
Croatian: Darunavir Apsolutna peroralna bioraspoloživost jednokratne doze od 600 mg samog darunavira je približno 37%.
English: Darunavir was not mutagenic or genotoxic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), chromosomal aberration in human lymphocytes and in vivo micronucleus test in mice.
Croatian: Darunavir nije bio mutagen ili genotoksičan u setu in vitro i in vivo testova uključujući reverznu bakterijsku mutaciju (Ames), kromosomsku aberaciju u ljudskim limfocitima te in vivo mikronukleusni test kod miševa.
English: Darunavir After a 400/100 mg
Croatian: Darunavir Nakon doze od 400/100 mg
English: Based on normal approximation to the difference in % response Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0
Croatian: Na temelju normalne aproksimacije razlike u % odgovora Bolesnik koji nije završio ispitivanje ubilježen je kao neuspjeh: bolesnicima koji su prijevremeno prekinuli ispitivanje pripisana je promjena jednaka 0
English: In rats, ossification changes in the spinal column and sternebrae of fetuses occurred at a dose that produced significant maternal toxicity.
Croatian: Osifikacijske promjene na kralježnici i sternebri fetusa štakora pojavile su se pri dozi koja je uzrokovala značajnu maternalnu toksičnost.
English: During the clinical development program (N = 3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir.
Croatian: Tijekom kliničkog razvojnog programa (N = 3063), hepatitis je prijavljen kod 0,5% bolesnika koji su primali kombiniranu antiretrovirusnu terapiju darunavirom/ritonavirom.
English: Appropriate laboratory testing should be conducted prior to initiating therapy with REZOLSTA and patients should be monitored during treatment.
Croatian: Prije početka terapije lijekom REZOLSTA moraju se provesti odgovarajuća laboratorijska ispitivanja, te se bolesnike mora pratiti tijekom liječenja.
English: Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency.
Croatian: U bolesnica koje koriste estrogene kao hormonsku nadomjesnu terapiju trebaju se klinički pratiti znakovi estrogenske deficijencije.
English: C-darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg darunavir with ritonavir dose was due to the parent active substance.
Croatian: C-darunavira na zdravim dobrovoljcima pokazalo je da većinu radioaktivnosti u plazmi nakon jednokratne doze od 400/100 mg darunavira s ritonavirom treba pripisati ishodišnoj djelatnoj tvari.
English: Atorvastatin (10 mg once daily): atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin ND
Croatian: Atorvastatin (10 mg jedanput na dan): atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin NO
English: REZOLSTA may have a minor influence on the ability to drive and use machines.
Croatian: REZOLSTA malo utječe utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Cobicistat inhibits the transporters p-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3.
Croatian: Kobicistat inhibira transportere p-glikoprotein (P-gp), BCRP, MATE1, OATP1B1 i OATP1B3.
English: Patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions.
Croatian: Bolesnici s već postojećom disfunkcijom jetre, uključujući kronični aktivni hepatitis B ili C, imaju povećani rizik za nastanak poremećaja funkcije jetre uključujući teške i potencijalno smrtonosne jetrene nuspojave.
English: The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer, therefore there may be different recommendations for the use of darunavir with concomitant medicine.
Croatian: Interakcijski profil darunavira ovisi o tome je li kao farmakokinetički pojačivač korišten ritonavir ili kobicistat, stoga su moguće različite preporuke za uzimanje darunavira s lijekovima u istodobnoj primjeni.
English: Darunavir Results from a mass balance study with
Croatian: Darunavir Rezultati ispitivanja masene bilance s
English: This protein binding is concentration dependent indicative for saturation of binding.
Croatian: Ovo vezanje na protein je ovisno o koncentraciji i pokazatelj je mogućnosti zasićenja vezanja.
English: Imputations according to the TLOVR algorithm Based on a normal approximation of the difference in % response Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX Difference in means
Croatian: Na temelju normalne aproksimacije razlike % odgovora Podtipovi A1, D, F1, G, K, CRF02_AG, CRF12_BF i CRF06_CPX Razlika srednjih vrijednosti
English: In clinical trials with darunavir/ritonavir and darunavir/cobicistat, rash was mostly mild to moderate, often occurring within the first four weeks of treatment and resolving with continued dosing (see section 4.4).
Croatian: U kliničkim ispitivanjima s darunavirom/ritonavirom i darunavirom/kobicistatom, osip je bio uglavnom blag do umjeren, a često se javljao unutar prva četiri tjedna liječenja i nestao je s nastavkom doziranja (vidjeti dio 4.4).
English: REZOLSTA must therefore not be combined with medicinal products that are highly dependent on CYP3A for clearance and for which increased systemic exposure is associated with serious and/or life-threatening events (narrow therapeutic index) (see section 4.3).
Croatian: REZOLSTA se stoga ne smije kombinirati s lijekovima čiji je klirens u velikoj mjeri ovisan o CYP3A i za koje je povećana sistemska izloženost povezana s ozbiljnim i/ili po život opasnim događajima (uski terapijski indeks) (vidjeti dio 4.3).
English: Increased monitoring for rifabutin associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin.
Croatian: Potreban je strogi nadzor nuspojava povezanih s rifabutinom, uključujući neutropeniju i uveitis zbog očekivanog povećanja izloženosti rifabutinu.
English: Paediatric population The pharmacokinetics of REZOLSTA in paediatric patients have not been investigated.
Croatian: Pedijatrijska populacija Farmakokinetika lijeka REZOLSTA u pedijatrijskih bolesnika nije bila ispitivana.
English: Description of clinical studies of darunavir/ritonavir in adults
Croatian: Opis kliničkih ispitivanja darunavira/ritonavira u odraslih
English: Monitoring of renal function may be indicated when REZOLSTA is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Croatian: Praćenje funkcije bubrega može biti indicirano kada se REZOLSTA daje u kombinaciji s tenofovirdizoproksilom, posebno kod bolesnika s podležećom sistemskom ili bubrežnom bolešću ili kod bolesnika koji uzimaju nefrotoksične lijekove.
English: It is recommended that the international normalised ratio (INR) be monitored when warfarin is co-administered with REZOLSTA.
Croatian: Preporučuje se praćenje internacionalnog normaliziranog omjera (INR) kada se varfarin primjenjuje istodobno s lijekom REZOLSTA.
English: The safety and efficacy of REZOLSTA, darunavir, or cobicistat have not been established in patients with severe underlying liver disorders.
Croatian: Sigurnost i djelotvornost lijeka REZOLSTA, darunavira ili kobicistata nisu ustanovljene kod bolesnika s teškim podležećim poremećajima jetre.
English: Pregnant or breast-feeding mothers should not take REZOLSTA.
Croatian: Trudnice ili dojilje ne smiju uzimati lijek REZOLSTA.
English: As darunavir and cobicistat are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis (see sections 4.2 and 5.2).
Croatian: S obzirom da darunavir i kobicistat imaju visok afinitet vezanja na proteine plazme, nije vjerojatno da bi se značajno uklonili hemodijalizom ili peritonealnom dijalizom (vidjeti dijelove 4.2 i 5.2).
English: Severe hepatic impairment could result in an increase of darunavir and/or cobicistat exposure and a worsening of its safety profile.
Croatian: Teško oštećenje jetre može rezultirati povećanom izloženošću darunaviru i/ili kobicistatu i pogoršati njegov sigurnosni profil.
English: No adjustment of methadone dosage is expected when initiating co-administration with REZOLSTA.
Croatian: Ne očekuje se prilagodba doze metadona kada se započinje istodobna primjena s lijekom REZOLSTA.
English: Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and P-glycoprotein (see section 4.5).
Croatian: Po život opasne i smrtonosne interakcije lijekova prijavljene su u bolesnika liječenih kolhicinom i snažnim inhibitorima CYP3A i P-glikoproteina (P-gp) (vidjeti dio 4.5).
English: Lurasidone Pimozide Sertindole Quetiapine
Croatian: Lurasidon Pimozid Sertindol Kvetiapin
English: Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 l (Mean ± SD) and increased to 131 ± 49.9 l (Mean ± SD) in the presence of 100 mg twice-daily ritonavir.
Croatian: Nakon intravenske primjene, volumen distribucije samog darunavira bio je 88,1 ± 59,0 l (srednja vrijednost ± SD) i povećao se na 131 ± 49,9 l (srednja vrijednost ± SD) u prisutnosti 100 mg ritonavira dva puta na dan.
English: - Apixaban, edoxaban, rivaroxaban, warfarin (to reduce clotting of the blood) as their therapeutic effect or side effects may be altered; your doctor may have to check your blood.
Croatian: - apiksaban, edoksaban, rivaroksaban, varfarin (smanjuju zgrušavanje krvi) jer njihov terapijski učinak ili nuspojave mogu biti izmijenjene; liječnik će Vam možda htjeti provjeriti krvnu sliku.
English: The table below shows the efficacy data of the 48 week analyses from the GS-US-216-130 trial:
Croatian: Tablica ispod pokazuje podatke djelotvornosti iz analize nakon 48 tjedana iz GS-US-216-130 ispitivanja:
English: (OATP1B and CYP3A inhibition)
Croatian: (OATP1B i CYP3A inhibicija)
English: In GS-US-216-130 baseline phenotype was not available
Croatian: Kod GS-US-216-130 fenotip na početku nije bio dostupan
English: Stevens-Johnson syndrome
Croatian: Stevens-Johnsonov sindrom #, angioedem,
English: The film-coating contains polyvinyl alcoholpartially hydrolyzed, titanium dioxide, polyethylene glycol (macrogol), talc, iron oxide red, and iron oxide black.
Croatian: Film ovojnica sadrži poli(vinilni alkohol) - djelomično hidroliziran, titanijev dioksid, polietilenglikol (makrogol), talk, željezov oksid, crveni i željezov oksid, crni.
English: Side effects with unknown frequency: a rash may become severe or potentially life-threatening: - rash with blisters and peeling skin over much of the body - red rash covered with small pus-filled bumps that can spread over the body, sometimes with a fever.
Croatian: Nuspojave s nepoznatom učestalošću: osip može postati težak ili potencijalno može ugroziti život: - osip s mjehurićima i ljuštenjem kože na većim površinama tijela - crveni osip prekriven malim uzdignućima ispunjenim gnojem koja se mogu proširiti po tijelu i ponekad mogu biti popraćena vrućicom.
English: Patients should be instructed to take REZOLSTA within 30 minutes after completion of a meal (see sections 4.4, 4.5 and 5.2).
Croatian: Bolesnike se mora uputiti da uzimaju lijek REZOLSTA unutar 30 minuta nakon završetka obroka (vidjeti dijelove 4.4, 4.5 i 5.2).
English: The most frequent adverse reactions reported during the darunavir/ritonavir clinical development program and as spontaneous reports are diarrhoea, nausea, rash, headache, and vomiting.
Croatian: Najčešće nuspojave prijavljene tijekom kliničkog razvojnog programa darunavira/ritonavira i spontano prijavljene su proljev, mučnina, osip, glavobolja i povraćanje.
English: Co-administration of REZOLSTA and rilpivirine can be used without dose adjustments, as the expected increase in rilpivirine concentrations is not considered clinically relevant.
Croatian: REZOLSTA s rilpivirinom se može istodobno primijeniti bez prilagodbe doze, jer se ne očekuje da će očekivani porast koncentracije rilpivirina biti klinički značajan.
English: The mean eGFRCG change from baseline was -9.6 mL/min at week 2, and -9.6 mL/min at week 48.
Croatian: Srednja vrijednost promjene eGFRCG u odnosu na početnu bila je -9,6 ml/min u 2. tjednu, i -9,6 ml/min u 48. tjednu.
English: Changes were observed in liver (hepatocyte hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular hypertrophy).
Croatian: Primijećene su promjene na jetri (hipertrofija hepatocita, vakuolizacija, povišeni enzimi jetre) i štitnjači (hipertrofija folikula).
English: REZOLSTA should not be used in combination with another antiretroviral that requires pharmacoenhancement since dosing recommendations for such combination have not been established.
Croatian: REZOLSTA se ne smije uzimati u kombinaciji s drugim antiretrovirusnim lijekom kojemu je potrebno farmakokinetičko pojačanje budući da preporuke doziranja za takve kombinacije nisu ustanovljene.
English: Rash occurred more commonly in treatment-experienced patients receiving regimens containing darunavir/ritonavir + raltegravir compared to patients receiving darunavir/ritonavir without raltegravir or raltegravir without darunavir/ritonavir (see section 4.8).
Croatian: Osip se javio češće u bolesnika koji su primali liječenje po režimima koji sadrže darunavir/ritonavir + raltegravir u usporedbi s bolesnicima koji su liječeni darunavirom/ritonavirom bez raltegravira ili raltegravirom bez darunavira/ritonavira (vidjeti dio 4.8).
English: This effect on serum creatinine, leading to a decrease in the estimated creatinine clearance, should be taken into consideration when REZOLSTA is administered to patients, in whom the estimated creatinine clearance is used to guide aspects of their clinical management, including adjusting doses of co-administered medicinal products.
Croatian: Ovaj učinak na kreatinin u serumu, koji dovodi do smanjenja procijenjenog klirensa kreatinina, mora se uzeti u obzir kada se REZOLSTA primjenjuje bolesnicima u kojih se na temelju procijenjenog klirensa kreatinina donose odluke o kliničkom liječenju, uključujući prilagodbu doza istodobno primijenjenih lijekova.
English: Otherwise, there were no effects on mating or fertility with darunavir treatment up to 1,000 mg/kg/day and exposure levels below (AUC-0.5 fold) of that in human at the clinically recommended dose.
Croatian: S druge strane, nije bilo učinka na parenje ili plodnost s liječenjem darunavirom do 1000 mg/kg/dan i razinama izloženosti ispod onih (AUC - 0,5 puta) kod klinički preporučenih doza za ljude.
English: The dosage of other medicines might need to be changed since either their own or REZOLSTA's therapeutic effect or side effects may be influenced when combined.
Croatian: Postoji mogućnost da će biti potrebno promijeniti doziranje drugih lijekova, s obzirom na mogućnost promjene terapijskog učinka ili nuspojava tih lijekova ili lijeka REZOLSTA kada se primjenjuju u kombinaciji.
English: REZOLSTA is, therefore, contraindicated in patients with severe hepatic impairment.
Croatian: REZOLSTA je stoga kontraindicirana kod bolesnika s teškim oštećenjem jetre.
English: OESTROGEN-BASED CONTRACEPTIVES Drospirenone (3 mg once daily)
Croatian: NA BAZI ESTROGENA Drospirenon (3 mg jedanput na dan)
English: Concentrations of voriconazole may increase or decrease when co-administered with REZOLSTA.
Croatian: Koncentracije vorikonazola mogu se povećati ili smanjiti kada se primjenjuju istodobno s lijekom REZOLSTA.